Document and Entity Information Statement [Table] Statement [Line Items] Statement Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Marketable Securities, Current Marketable securities Accounts Receivable, Net, Current Accounts receivable, net Inventory, Net Inventories, net Total inventories Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Marketable Securities, Noncurrent Long term marketable securities Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Net book value of intangible assets Other Assets, Noncurrent Other non-current assets Deferred Tax Assets, Net, Noncurrent Deferred income taxes Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Represent the amount of accrued sales deduction. Accrued Sales Deduction Accrued sales deductions Accrued Liabilities, Current Accrued expenses Total Accrued Income Taxes, Current Income taxes payable Current portion of debt due within one year or the normal operating cycle, if longer, related to the sale of future royalties, for which the creditor does not have general recourse to the debtor but rather has recourse only to the property used for collateral in the transaction or other specific property. Non Recourse Debt Sale of Future Royalties Current Non-recourse liability related to sale of future royalties, current portion Represents the carrying amount of licensing consideration received or receivable, as of the balance sheet date, on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer. Deferred Revenue Licensing Current Deferred licensing revenue Liabilities, Current Total current liabilities Represents the licensing revenue received, but not recognized for financial reporting purposes, which is anticipated to be recognized for financial reporting purposes more than one year from the reporting date or one operating cycle, if longer. Deferred Revenue Licensing Noncurrent Deferred licensing revenue, net of current portion Convertible Notes Payable, Noncurrent Remaining outstanding balance Convertible notes, net Noncurrent portion of debt, net of the amount due within one year or the normal operating cycle, if longer, related to the sale of future royalties, for which the creditor does not have general recourse to the debtor but rather has recourse only to the property used for collateral in the transaction or other specific property. Non Recourse Debt Sale of Future Royalties Noncurrent Non-recourse liability related to sale of future royalties, long term Other Liabilities, Noncurrent Other non-current liabilities Derivative Liability, Noncurrent Derivative liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock, $0.001 par value, 130,000,000 shares authorized at September 30, 2017 and December 31, 2016; 51,262,007 and 49,971,267 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss), net of tax Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Ending balance Beginning balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Consolidated Statements of Operations Revenues [Abstract] Revenue Revenue, Net Net product sales Royalty Revenue Royalty revenue Licenses Revenue Licensing revenue Revenues Total revenue Costs and Expenses [Abstract] Costs and expenses Cost of Goods Sold Cost of product sales Research and Development Expense Research and development Selling, General and Administrative Expense Selling, general and administrative Costs and Expenses Total costs and expenses Operating Income (Loss) Operating income Nonoperating Income (Expense) [Abstract] Other income (expense) Investment Income, Interest Interest income Interest Expense Interest expense Interest incurred in the period on the non-recourse sale of future royalty liability arrangement that was charged against earnings. Interest Expense Non Recourse Royalty Liability Interest expense-nonrecourse liability related to sale of future royalties Non-cash interest expense on non-recourse liability related to sale of future royalties Noncash interest expense Gain (Loss) on Derivative Instruments, Net, Pretax Changes in fair value of derivative liabilities Gains (Losses) on Extinguishment of Debt Loss on extinguishment of debt Loss on extinguishment of debt Nonoperating Income (Expense) Total other income (expense) Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Earnings before income taxes Income Tax Expense (Benefit) Income tax expense Income tax expense (benefit) Net Income (Loss) Attributable to Parent Net income Net income Earnings Per Share, Basic and Diluted [Abstract] Earnings per share: Earnings Per Share, Basic Net income per share, basic Basic (in dollars per share) Earnings Per Share, Diluted Diluted (in dollars per share) Net income per share, diluted Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Basic Basic (in shares) Weighted average shares outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Diluted (in shares) Weighted average shares outstanding, diluted Consolidated Statements of Comprehensive Income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Unrealized net gain (loss) on marketable securities, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive income (loss): Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Unrealized Gain (Loss) on Derivatives Change in fair value of derivative liability Depreciation, Depletion and Amortization Depreciation and amortization Amortization of Financing Costs and Discounts Amortization of deferred financing costs and debt discount Accretion of debt discount and deferred financing costs Represents the amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments netted against noncash interest income. Noncash interest income is the combination of the amount of amortization of purchase premium on non-operating securities and the amount of accretion of purchase discount on non-operating securities. Noncash Interest Expense (Income) Non-cash interest expense, net/ interest (income), net Represents revenue from the sale of certain royalty and milestone rights. Revenue From Royalty Agreement Non-cash royalty revenue Share-based Compensation Share-based compensation expense Deferred Income Tax Expense (Benefit) Deferred income tax provision Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventories Amount of increase (decrease) in prepaid expenses, and other current assets. Increase Decrease In Prepaid Deferred Expense And Other Current Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable Accounts payable The increase (decrease) during the reporting period in the aggregate amount of accrued sales deduction. Increase Decrease In Accrued Sales Deductions Accrued sales deductions Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Income Taxes Payable Income taxes payable Represents the increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting licensing revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Increase (Decrease) in Deferred Licensing Revenue Deferred licensing revenue Increase (Decrease) in Other Noncurrent Liabilities Other non-current liabilities Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities Payments to Acquire Marketable Securities Purchases of marketable securities Proceeds from Sale and Maturity of Marketable Securities Sales and maturities of marketable securities Payments to Acquire Property, Plant, and Equipment Purchases of property, plant and equipment Payments to Acquire Intangible Assets Deferred legal fees Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental cash flow information: Interest Paid, Net Cash paid for interest Noncash Investing and Financing Items [Abstract] Noncash financial activity: The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction as well as the interest make-whole. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Debt Conversion, Converted Instrument And Interest Make Whole Amount Conversion of convertible notes and interest make-whole Represents the non cash expenses related to intangible assets that were capitalized and shown within accrued expenses. Non Cash Capitalized Cost Of Intangible Assets Deferred legal fees included in accounts payable and accrued expenses Organization and Business Nature of Operations [Text Block] Organization and Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Inventories Inventory Disclosure [Text Block] Inventories Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Intangible Assets Intangible Assets Disclosure [Text Block] Intangible Assets Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Convertible Senior Secured Notes Long-term Debt [Text Block] Convertible Senior Secured Notes Summary Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Summary Stockholders' Equity Share-Based Payments Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share-Based Payments Earnings per Share Earnings Per Share [Text Block] Earnings per Share Income Taxes Income Tax Disclosure [Text Block] Income Taxes Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Collaboration Agreement Collaborative Arrangement Disclosure [Text Block] Collaboration Agreement Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Marketable Securities, Policy [Policy Text Block] Marketable Securities Trade and Other Accounts Receivable, Policy [Policy Text Block] Accounts Receivable, net Inventory, Policy [Policy Text Block] Inventories Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Intangible Assets, Finite-Lived, Policy [Policy Text Block] Intangible Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Represent the disclosure of accounting policy for the deferred financing costs. Deferred Financing Costs [Policy Text Block] Deferred Financing Costs Disclosure of accounting policy for preclinical study and clinical trial accruals and deferred advance payments. Preclinical Study and Clinical Trial Accruals and Deferred Advance Payments [Policy Text Block] Preclinical Study and Clinical Trial Accruals Disclosure of accounting policy of sales of products. Revenue Recognition Sales Of Products [Policy Text Block] Revenue from Product Sales Revenue Recognition, Revenue Reductions [Policy Text Block] Sales Deductions Revenue Recognition, Services, Licensing Fees [Policy Text Block] Revenue Recognition of License Revenue Revenue Recognition, Services, Royalty Fees [Policy Text Block] Royalty Revenue Cost of Sales, Policy [Policy Text Block] Cost of Product Sales Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block] Advertising Expense Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-Based Compensation Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Property, Plant and Equipment [Table Text Block] Schedule of useful lives used to compute depreciation and amortization Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of financial instruments Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Schedule of fair value of the financial assets and liabilities Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of unrestricted marketable securities Investments Classified by Contractual Maturity Date [Table Text Block] Schedule of contractual maturities of the unrestricted available for sale marketable securities held Schedule of Inventory, Current [Table Text Block] Schedule of inventories Tabular disclosure of the components of property, plant and equipment. Schedule of Property Plant and Equipment Components [Table Text Block] Schedule of property and equipment Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Schedule of gross carrying amount and related accumulated amortization of the intangible asset Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Convertible Debt [Table Text Block] Summary of issuance of Notes reflected in balance sheet Schedule of Stockholders Equity [Table Text Block] Schedule of activity in certain captions within Stockholders' Equity Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of share-based compensation recognized related to the grant of employee and non-employee stock options, SAR, Employee Stock Purchase Plan (ESPP) awards and non-vested stock Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option and SAR activity Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of common stock equivalents excluded in the calculation of diluted income per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted net income per share Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Summary of our income tax expense and effective tax rate Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of future minimum lease payments under non-cancelable operating leases Represents the number of proprietary products and several proprietary product candidates in clinical development addresses address large market opportunities in epilepsy and attention deficit hyperactivity disorder. Number of Proprietary Products in Clinical Development Number of proprietary products in clinical development Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Marketable Securities - Restricted Basis of Presentation [Abstract] Basis of Presentation Number of Operating Segments Number of operating segments Defined Benefit Plans and Other Postretirement Benefit Plans [Axis] Defined Benefit Plans [Domain] Defined Benefit Plan and Other Postretirement Benefit Plan [Domain] Supplemental Employee Retirement Plan Defined Benefit [Member] SERP Defined Benefit Plan, Assets for Plan Benefits, Noncurrent Marketable securities Marketable securities - restricted (SERP) Concentration Risk [Table] Long-term Debt, Type [Axis] Longterm Debt Type [Domain] Long-term Debt, Type [Domain] Convertible Notes Payable [Member] 7.50% Convertible Senior Secured Notes due 2019 Concentration Risk [Line Items] Concentration risk percentage Accounts Receivable, Net [Abstract] Accounts Receivable, net Represents the allowance for sales deductions, which may include expected prompt-pay discounts and wholesaler fees. Allowance for Expected Sales deductions Allowance for expected sales discounts Debt Instrument, Interest Rate, Stated Percentage [Abstract] Deferred Financing Costs Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Computer Equipment [Member] Computer equipment Computer Software Intangible Asset [Member] Software Represents information pertaining to lab equipment and furniture. Lab Equipment And Furniture [Member] Lab equipment and furniture Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Property, Plant and Equipment [Line Items] Property and equipment Property, Plant and Equipment, Useful Life Useful lives Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Notes payable Revenue Recognition Represents the period within which a product can be returned by the customers to the entity prior to the expiry date. Sales Return Period Prior To Expiration Sales return period prior to expiry date Represents the period within which a product can be returned by the customers to the entity subsequent to the expiry date. Sales Return Period Sales return period subsequent to expiry date Revenue Recognition, Milestone Method, Revenue Recognized Milestone revenues recorded Marketing and Advertising Expense [Abstract] Advertising Expense Advertising Expense Advertising costs New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Recently Issued Accounting Pronouncements Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Inputs Level1 [Member] Quoted Prices in Active Markets (Level 1) Fair Value Inputs Level2 [Member] Significant Other Observable Inputs (Level 2) Fair Value Inputs Level3 [Member] Significant Unobservable Inputs (Level 3) Assets, Fair Value Disclosure [Abstract] Assets: Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Assets, Fair Value Disclosure Total assets at fair value Liabilities, Fair Value Disclosure [Abstract] Liabilities: Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Line Items] Unrestricted marketable securities Available-for-sale Securities, Amortized Cost Basis Corporate debt securities, Amortized Cost Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Corporate debt securities, Gross Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Corporate debt securities, Gross Unrealized Losses Available-for-sale Securities Corporate debt securities, Fair Value Corporate debt securities, Fair Value Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract] Contractual maturities of the unrestricted available for sale marketable securities held Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Less Than 1 Year Fair value of available-for-sale debt securities maturing after the first year through the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Available For Sale Securities Debt Maturities After One Through Two Years Fair Value 1 year to 2 years Fair value of available-for-sale debt securities maturing in the third fiscal year through the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value 3 years to 4 years Inventory, Work in Process and Raw Materials, Net of Reserves Raw materials Inventory, Work in Process, Net of Reserves Work in process Inventory, Finished Goods, Net of Reserves Finished goods Leasehold Improvements [Member] Leasehold improvements Property, Plant and Equipment, Gross Property and equipment, gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization expense Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite Lived Intangible Assets Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents [Member] Purchased patents Represents information pertaining to Trokendi XR patent litigation. Trokendi Xr [Member] Trokendi XR patent litigation Represents information concerning the capitalized patent defense costs related to the Watson litigation. Patent Defense Costs [Member] Capitalized patent defense costs Finite-Lived Intangible Assets [Line Items] Intangible Assets Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Weighted-Average Life Finite-Lived Intangible Assets, Gross Gross Carrying Amount Finite-Lived Intangible Assets, Accumulated Amortization Less accumulated Amortization Intangible Assets, Net (Excluding Goodwill) [Abstract] Additional disclosures Represents the number of settlements. Number of Settlements Number of settlements Amortization of Intangible Assets Amortization expense Employee-related Liabilities, Current Accrued compensation Accrued Professional Fees, Current Accrued professional fees Represents the amount of clinical trial and clinical supply costs accrued. Accrued Clinical Trial and Clinical Supply Costs Current Accrued clinical trial and clinical supply costs Represents the amount of product costs accrued. Accrued Product Costs Current Accrued product costs Interest Payable, Current Accrued interest expense Other Accrued Liabilities, Current Other accrued expenses Debt Instrument Convertible Additional Information [Abstract] Details of Notes reflected in balance sheet Proceeds from Issuance of Debt Gross proceeds Represents the fair value of the interest make whole derivative reported as debt discount. Fair Value of Interest Make Whole Derivative Initial value of interest make-whole derivative reported as debt discount Conversion option that has been reported as an adjustment to additional paid in capital (APIC) including conversion feature and debt discount. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature and Debt Discount Conversion option reported as debt discount and APIC Debt Conversion, Original Debt, Amount Conversion of debt to equity - principal For debt that has been converted to equity, the amount of amortization expense attributable to debt discount (premium) and debt issuance costs. Amortization Of Financing Costs And Discounts Conversion Of Debt To Equity Conversion of debt to equity - accretion of debt discount and deferred financing costs Debt Conversion, Converted Instrument, Shares Issued Shares of common stock issued in conversion of Notes Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption. Cumulative Effect of New Accounting Principle in Period of Adoption Duration Cumulative-effect adjustment Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Share-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Employee Stock Purchase Program, Requisite Service Period Recognition Issuance of ESPP shares Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Exercise of stock options Stock Issued During Period, Value, Conversion of Convertible Securities Equity issued on note conversion Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Represents information pertaining to the 2012 Equity Incentive Plan that provides for grants of stock options, purchase rights and awards to employees, officers, directors, consultants or advisors. Equity Incentive Plan2012 [Member] 2012 Plan Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] Employee Stock Option [Member] Stock Option Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based payments Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Maximum number of shares of common stock provided for issuance Represents the number of installments in which the awards would generally vest starting from the first anniversary of the date of grant. Share Based Compensation Arrangement by Share Based Payment Award, Award Vesting Number of Installments from First Anniversary of Grant Date Number of annual installments in which the awards would generally vest starting on the first anniversary of the date of grant Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Contractual term Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research And Development Expense [Member] Research and development Selling General And Administrative Expenses [Member] Selling, general and administrative Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Payments Allocated Share-based Compensation Expense Share-based compensation recognized Represents information related to stock option awards for employees and non-employees as well as stock appreciation rights. Stock Option Stock Appreciation Rights [Member] Stock option and Stock Appreciation Rights Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Options and SAR Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at the end of the period (in shares) Outstanding at the beginning of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at the end of the period (in dollars per share) Outstanding at the beginning of the period (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Forfeited or expired (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Weighted-Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Represents stock options, stock appreciation rights and employee stock purchase plan. Stock Options Stock Appreciation Rights And Employee Stock Purchase Plan Awards [Member] Stock options, stock appreciation rights, and ESPP awards Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Income per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Common stock equivalents excluded in the calculation of diluted income per share Numerator, in thousands: Net Income (Loss) Available to Common Stockholders, Basic Net income used for calculation of basic EPS The amount of interest recognized in the period including interest expense adjustments, associated with any convertible debt. Interest On Convertible Debt Including Adjustments Interest expense on convertible debt The increase (decrease) during the period in the fair value of derivative instruments reported as liabilities. Increase Decrease in Fair Value Derivative Liabilities Changes in fair value of derivative liabilities Difference between the fair value of payments made and the carrying amount of outstanding debt which is extinguished prior to maturity. Gains Losses On Extinguishment of Outstanding Debt Loss on extinguishment of debt Difference between the fair value of payments made and the carrying amount of outstanding debt as if converted which is extinguished prior to maturity. Gains Losses on Extinguishment of Outstanding Debt as if Converted Loss on extinguishment of outstanding debt, as if converted Dilutive Securities, Effect on Basic Earnings Per Share Total adjustments Net income used for calculation of diluted EPS Net income used for calculation of diluted EPS Denominator: Effect of dilutive potential common shares: Shares underlying Convertible Senior Secured Notes and interest make-whole Shares underlying Convertible Senior Secured Notes Represents the information relating to shares issuable to settle interest make-whole derivatives. Incremental Common Shares Attributable To Settlement Of Interest Make Whole Derivates Shares issuable to settle interest make-whole derivatives Weighted Average Number of Shares, Employee Stock Ownership Plan Shares Not Committed to be Released Stock options and stock appreciation rights Weighted Average Number Diluted Shares Outstanding Adjustment Total potential dilutive common shares Effective Income Tax Rate Reconciliation, Percent Effective tax rate Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Excess tax benefits related to employee exercise of stock options Represents the additional period for which the entity may extend the operating lease term. Operating Leases Optional Lease Extension Period Additional period for which the entity may elect to extend the term of the lease Represents the additional amount of payments that the lessee can elect to make in connection with tenant and capital improvement allowances under the terms of an agreement classified as an operating lease. Operating Leases Additional Allowance for Tenant and Capital Improvement Additional tenant improvement allowance Represents the amount of allowances for tenant and capital improvements that have been utilized and capitalized by the entity. Operating Leases Allowance for Tenant and Capital Improvement Capitalized Tenant improvement allowance utilized Represents the amount available for tenant improvements. Operating Leases Amount Available For Tenant Improvements Amount available for tenant improvements Operating Leases, Rent Expense Rent expense Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Future minimum lease payments under non-cancelable operating leases Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2017 (remaining) Operating Leases, Future Minimum Payments, Due in Two Years 2018 Operating Leases, Future Minimum Payments, Due in Three Years 2019 Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Operating Leases Future Minimum Payments Due After Three Years Thereafter Operating Leases, Future Minimum Payments Due Total The amount of milestone payments due under the purchase and sale agreement. Milestone Payments Due Milestone payments due Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Information by collaborative arrangements. Collaborative Arrangements Transactions [Axis] The collective collaborative arrangements, which are contractual arrangements with a party or parties that both: (i) actively participate in a joint operating activity and (ii) is (are) exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Collaborative Arrangements Transactions [Domain] Collaborative Arrangements Transactions [Domain] Collaborative Arrangement [Member] Collaborative Arrangement Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Represents information pertaining to United Therapeutics, with whom the entity has entered into a license agreement. United Therapeutics [Member] United Therapeutics Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaboration agreement Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Noncurrent Assets [Member] Other Non-current Assets Adjustments for New Accounting Pronouncements [Axis] Type Of Adoption [Member] Type of Adoption [Domain] Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. Accounting Standards Update201609 [Member] ASU 2016-09 Scenario [Axis] Scenario Unspecified [Domain] Scenario, Unspecified [Domain] Domain member used to indicate figures that are adjustments during a period or as of a point in time related to cumulative effect adjustments. This domain member would never be expected to appear in a relationship group without the "Scenario, Previously Reported" Member with the same parent. Scenario Adjustment For Cumulative Effect [Member] Cumulative Effect Adjustment Domain member used to indicate figures that are adjustments during a period or as of a point in time related to deferred tax asset adjustments. This domain member would never be expected to appear in a relationship group without the "Scenario, Previously Reported" Member with the same parent. Scenario Adjustment For Deferred Tax Asset [Member] Deferred Tax Asset Adjustment Measurement Basis [Axis] Portion At Fair Value Fair Value Disclosure [Member] Portion at Fair Value Measurement [Member] Carrying Reported Amount Fair Value Disclosure [Member] Total Carrying Value Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Recurring [Member] Recurring Construction In Progress [Member] Construction in progress Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit Title of Individual [Axis] Title Of Individual With Relationship To Entity [Domain] Relationship to Entity [Domain] Director [Member] Directors Related Party [Axis] Related Party [Domain] Related Party [Domain] Pertains to Rune HealthCare Limited (Rune). Rune Healthcare Limited [Member] Rune HealthCare Limited